Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer-Reference-Cited by-同舟云学术

Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer

Published:2015-07-01 Issue:5 Volume:33 Page:1108-1114
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Tolaney Sara M.,Tan Sally,Guo Hao,Barry William,Van Allen Eliezer,Wagle Nikhil,Brock Jane,Larrabee Katherine,Paweletz Cloud,Ivanova Elena,Janne Pasi,Overmoyer Beth,Wright John J.,Shapiro Geoffrey I.,Winer Eric P.,Krop Ian E.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-015-0269-8.pdf

Reference28 articles.

1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29. doi: 10.3322/caac.21208

2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752

3. Eroles P, Bosch A, Perez-Fidalgo JA, Lluch A (2012) Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev 38(6):698–707. doi: 10.1016/j.ctrv.2011.11.005

4. Boix L, Rosa JL, Ventura F, Castells A, Bruix J, Rodes J, Bartrons R (1994) c-met mRNA overexpression in human hepatocellular carcinoma. Hepatology 19(1):88–91

5. Kuniyasu H, Yasui W, Yokozaki H, Kitadai Y, Tahara E (1993) Aberrant expression of c-met mRNA in human gastric carcinomas. Int J Cancer 55(1):72–75

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Molecular Profiling on Therapy Management in Breast Cancer;Journal of Clinical Medicine;2024-08-23

2. Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer;Cancer Letters;2024-04

3. Targeted Treatment of Metastatic Triple‐Negative Breast Cancer: A Systematic Review;The Breast Journal;2024-01

4. Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type;Cancers;2023-04-08

5. Scaffold Repurposing Reveals New Nanomolar Phosphodiesterase Type 5 (PDE5) Inhibitors Based on Pyridopyrazinone Scaffold: Investigation of In Vitro and In Silico Properties;Pharmaceutics;2022-09-15